European Radiology

, Volume 21, Issue 2, pp 281–290 | Cite as

The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study

  • Maïté Lewin
  • Laetitia Fartoux
  • Alexandre Vignaud
  • Lionel Arrivé
  • Yves Menu
  • Olivier Rosmorduc



To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment.

Materials and methods

Two target tumors were prospectively analyzed in 12 patients at baseline, 2-weeks and 2-months treatment using b values of 0, 200, 400, 800 s/mm. Repeatability error was estimated on a healthy volunteer.


Lesion sizes, ADC and D values did not significantly change during treatment (overall mean values, respectively, 47.8 ± 31.0 mm, 1.34 ± 0.14 × 10−3 mm2/s and 1.18 ± 0.22 × 10−3 mm2/s). However, f values significantly increased in seven responder patients (+38.39% at 2-weeks, +50.94% at 2-months, P = 0.005) while they decreased in five non responder patients (−41.93% at 2-weeks, P = 0.006). Furthermore, f was inversely correlated with αFP levels (P = 0.032) and responder patients had a higher mean overall survival (OS) than non responder patients (12.29 ± 4.46 vs. 7.80 ± 4.97 months). The % variation of f relative to baseline at 2-months was correlated with OS (P = 0.038) and symptomatic time to progression (P = 0.022).


Contrary to ADC and D, the perfusion fraction f is a valuable marker of sorafenib treatment in advanced HCC.


Diffusion coefficient Perfusion fraction Hepatocellular carcinoma Anti-angiogenics Sorafenib Response assessment 


  1. 1.
    Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMedGoogle Scholar
  2. 2.
    Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMedGoogle Scholar
  3. 3.
    Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622–1635CrossRefPubMedGoogle Scholar
  4. 4.
    Le Bihan D, Breton E, Lallemand D et al (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168:497–505PubMedGoogle Scholar
  5. 5.
    Yamada I, Aung W, Himeno Y et al (1999) Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 210:617–623PubMedGoogle Scholar
  6. 6.
    Lewin M, Poujol-Robert A, Boëlle PY et al (2007) Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46:658–665CrossRefPubMedGoogle Scholar
  7. 7.
    Luciani A, Vignaud A, Cavet M et al (2008) Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 249:891–899CrossRefPubMedGoogle Scholar
  8. 8.
    Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–66CrossRefPubMedGoogle Scholar
  9. 9.
    Kamel IR, Liapi E, Reyes DK et al (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemobolization as detected with MR imaging. Radiology 250:466–473CrossRefPubMedGoogle Scholar
  10. 10.
    Chen CY, Li CW, Kuo YT et al (2006) Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants-initial experience. Radiology 239:448–456CrossRefPubMedGoogle Scholar
  11. 11.
    Schraml C, Schwenzer NF, Martirosian P et al (2009) Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 193:W301–W307CrossRefPubMedGoogle Scholar
  12. 12.
    Jain RK, Duda DG, Willett CG et al (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327–338CrossRefPubMedGoogle Scholar
  13. 13.
    Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41:864–880CrossRefPubMedGoogle Scholar
  14. 14.
    Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRefPubMedGoogle Scholar
  15. 15.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMedGoogle Scholar
  16. 16.
    Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMedGoogle Scholar
  17. 17.
    Forner A, Ayuso C, Varela M et al (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMedGoogle Scholar
  18. 18.
    Koh DM, Blackledge M, Collins DJ et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19:2728–2738CrossRefPubMedGoogle Scholar
  19. 19.
    Lewin M, Arrivé L, Lacombe C et al (2010) Diffusion-weighted MR imaging of liver pathology: principles and clinical applications. J Radiol 91:11–26CrossRefPubMedGoogle Scholar
  20. 20.
    Taouli B, Vilgrain V, Dumont E et al (2003) Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226:71–78CrossRefPubMedGoogle Scholar
  21. 21.
    Parikh T, Drew SJ, Lee VS et al (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246:812–822CrossRefPubMedGoogle Scholar
  22. 22.
    Gourtsoyianni S, Papanikolaou N, Yarmenitis S et al (2008) Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol 18:486–492CrossRefPubMedGoogle Scholar
  23. 23.
    Namimoto T, Yamashita Y, Sumi S et al (1997) Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 204:739–744PubMedGoogle Scholar
  24. 24.
    Kim T, Murakami T, Takahashi S et al (1999) Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 173:393–398PubMedGoogle Scholar
  25. 25.
    Bruegel M, Holzapfel K, Gaa J et al (2008) Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 18:477–485CrossRefPubMedGoogle Scholar
  26. 26.
    Kamel IR, Bluemke DA, Ramsey D et al (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181:708–710PubMedGoogle Scholar
  27. 27.
    Mannelli L, Kim S, Hajdu CH et al (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193:1044–1052CrossRefPubMedGoogle Scholar
  28. 28.
    Horger M, Lauer UM, Schraml C et al (2009) Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 9:208CrossRefPubMedGoogle Scholar
  29. 29.
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62CrossRefPubMedGoogle Scholar
  30. 30.
    Mitsuhashi N, Kobayashi S, Doki T et al (2008) Clinical significance of a-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol 23:e189–e197CrossRefPubMedGoogle Scholar
  31. 31.
    Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2010

Authors and Affiliations

  • Maïté Lewin
    • 1
    • 3
    • 5
  • Laetitia Fartoux
    • 2
  • Alexandre Vignaud
    • 4
  • Lionel Arrivé
    • 1
    • 3
  • Yves Menu
    • 1
    • 3
  • Olivier Rosmorduc
    • 2
    • 3
  1. 1.Departments of RadiologySaint-Antoine Hospital, Assistance Publique-Hôpitaux de ParisParisFrance
  2. 2.Departments of HepatologySaint-Antoine Hospital, Assistance Publique-Hôpitaux de ParisParisFrance
  3. 3.University Paris VI Pierre et Marie CurieParisFrance
  4. 4.France and Siemens Medical DepartmentSaint-DenisFrance
  5. 5.Service de RadiologieHôpital Saint AntoineParisFrance

Personalised recommendations